BrainStorm Cell Therapeutics is currently conducting a Phase I/II clinical trial to test the tolerability and safety, as well as collect preliminary efficacy data on their NurOwn technology for the treatment of ALS. The study is being conducted at the Hadassah University Medical Center in Jerusalem. In July, BrainStorm reported that they had successfully treated 12 patients enrolled in the trial, with none of the 12 patients reporting any side effects. Upon FDA approval, BrainStorm plans to initiate a Phase II trial of NurOwn in people with ALS in the United States. Recently, Dr. Adrian Harel, the CEO of BrainStorm, was interviewed about their Phase I/II study of NurOwn.
Click here to read more.Share this: